MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314254 | Name: Ombitasvir
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ombitasvir, also known as ABT-267, is a NS5A inhibitor, and is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak. Ombitasvir acts by inhibiting the HCV protein NS5A.

Chemical Structure

Ombitasvir
Ombitasvir
CAS#1258226-87-7

Theoretical Analysis

MedKoo Cat#: 314254

Name: Ombitasvir

CAS#: 1258226-87-7

Chemical Formula: C50H67N7O8

Exact Mass: 893.5051

Molecular Weight: 894.13

Elemental Analysis: C, 67.17; H, 7.55; N, 10.97; O, 14.32

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
100mg USD 750.00 2 Weeks
250mg USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ABT-267; ABT267; ABT 267; Ombitasvir; Viekira Pak.
IUPAC/Chemical Name
L-Prolinamide,2,2'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(N-(methoxycarbonyl)-L-valyl-
InChi Key
ZLLNJSXORCIMOQ-CTWGVMPISA-N
InChi Code
InChI=1S/C50H67N7O8/c1-30(2)49(53-46(62)64-8,44(60)55-28-10-12-40(55)42(51)58)35-18-14-32(15-19-35)38-26-27-39(57(38)37-24-22-34(23-25-37)48(5,6)7)33-16-20-36(21-17-33)50(31(3)4,54-47(63)65-9)45(61)56-29-11-13-41(56)43(52)59/h14-25,30-31,38-41H,10-13,26-29H2,1-9H3,(H2,51,58)(H2,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,49+,50+/m0/s1
SMILES Code
CC([C@H](NC(OC)=O)C(N1CCC[C@H]1C(NC2=CC=C([C@@H]3CC[C@@H](C4=CC=C(NC([C@@H]5CCCN5C([C@@H](NC(OC)=O)C(C)C)=O)=O)C=C4)N3C6=CC=C(C(C)(C)C)C=C6)C=C2)=O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
dmf 30.0 33.55
DMSO 54.3 60.77
Ethanol 30.0 33.55
Ethanol:PBS (pH 7.2) (1:2) 0.3 0.34
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 894.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Miura M, Nishino M, Kawaguchi K, Li S, Shimakami T, Tamai T, Nakagawa H, Terashima T, Iida N, Takatori H, Arai K, Sakai Y, Yamashita T, Honda M, Kaneko S, Mizukoshi E, Yamashita T. Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy. PLoS One. 2024 May 23;19(5):e0299424. doi: 10.1371/journal.pone.0299424. PMID: 38781172; PMCID: PMC11115325. 2: Moon C, Porges E, Roberts A, Bacon J. A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication. Antiviral Res. 2024 May;225:105859. doi: 10.1016/j.antiviral.2024.105859. Epub 2024 Mar 14. PMID: 38492891. 3: Said EM, Abdulaziz BA, Kassas ME, El Attar IH, Emadeldeen M, Abd-Elsalam SM. Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real- life experience. Arch Virol. 2024 Feb 13;169(3):45. doi: 10.1007/s00705-024-05990-z. PMID: 38349452. 4: Aziz S, Waqas M, Naz HF, Halim SA, Jan A, Muhsinah AB, Khan A, Al-Harrasi A. Identification of novel compounds and repurposing of FDA drugs for 1-deoxy-D- xylulose 5-phosphate reductoisomerase enzyme of Plasmodium falciparum to combat malaria resistance. Int J Biol Macromol. 2024 Feb;257(Pt 2):128672. doi: 10.1016/j.ijbiomac.2023.128672. Epub 2023 Dec 11. PMID: 38092105. 5: Chen R, Xiong Y, Zeng Y, Wang X, Xiao Y, Zheng Y. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis. Front Public Health. 2023 Sep 29;11:1179531. doi: 10.3389/fpubh.2023.1179531. PMID: 37841743; PMCID: PMC10570741. 6: Sahin A, Akay O. Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey. Ann Saudi Med. 2023 Sep- Oct;43(5):308-314. doi: 10.5144/0256-4947.2023.308. Epub 2023 Oct 5. PMID: 37805816; PMCID: PMC10560371. 7: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Ombitasvir. 2023 Sep 15. PMID: 29999879. 8: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Dasabuvir. 2023 Sep 15. PMID: 29999876. 9: Sølund C, Pedersen MS, Fahnøe U, Filskov J, Jenssen H, Weis N, Schønning K, Bukh J. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals. APMIS. 2023 Aug;131(8):426-433. doi: 10.1111/apm.13335. Epub 2023 Jun 25. PMID: 37355962. 10: Huang M, Saragih M, Tambunan USF. In silico Antivirus Repurposing and its Modification to Organoselenium Compounds as SARS-CoV-2 Spike Inhibitors. Pak J Biol Sci. 2023 Jan;26(2):81-90. doi: 10.3923/pjbs.2023.81.90. PMID: 37265039. 11: Pinchera B, Scotto R, Zappulo E, Buonomo AR, Maraolo AE, Schiano Moriello N, Viceconte G, Cattaneo L, Villari R, Gison F, De Filippis F, Ercolini D, Gentile I. Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study. New Microbiol. 2023 May;46(2):196-201. PMID: 37247240. 12: El-Marakby MG, Solayman MH, Sabri NA. Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study. Ther Innov Regul Sci. 2023 Sep;57(5):997-1007. doi: 10.1007/s43441-023-00537-x. Epub 2023 May 25. PMID: 37227588; PMCID: PMC10400676. 13: El-Ghandour A, Youssif T, Ibrahim W, Abdelsattar HA, Bawady SAE, Wagih M, El-Nakeep S. The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients. Egypt J Intern Med. 2023;35(1):12. doi: 10.1186/s43162-023-00197-1. Epub 2023 Feb 13. PMID: 36816629; PMCID: PMC9922615. 14: El-Sayed M, Elserafy M, El Raziky M, Elakel W, Saad Y, Fayad T, Korany M, Mehrez M, Salama R, Mahrous M, Zaki A, Hassany M, Ammar I, Elsaeed K, Elshazly Y, Doss W. Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease. Arab J Gastroenterol. 2023 Feb;24(1):29-33. doi: 10.1016/j.ajg.2022.10.001. Epub 2023 Feb 20. PMID: 36813580. 15: Martínez-Campreciós J, Riveiro-Barciela M, Muñoz-Gómez R, Londoño MC, Roget M, Serra MÁ, Escudero-García D, Purchades L, Rodríguez M, Losa-García JE, Gutiérrez ML, Carmona I, García-Samaniego J, Morano L, Martín-Granizo I, Montero-Alonso M, Prieto M, Delgado M, Ramos N, Azancot MA, Rodríguez-Frías F, Buti M. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. Gastroenterol Hepatol. 2023 Oct;46(8):594-602. English, Spanish. doi: 10.1016/j.gastrohep.2022.12.004. Epub 2022 Dec 27. PMID: 36584754. 16: Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C. World J Clin Cases. 2022 Dec 6;10(34):12566-12577. doi: 10.12998/wjcc.v10.i34.12566. PMID: 36579085; PMCID: PMC9791528. 17: Gheorghe L, Preda C, Trifan A, Manuc M, Stanciu C, Istratescu D, Popescu CP, Diculescu MM, Tieranu CG, Manuc T, Stroie TG, Iacob SM, Iliescu L. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. J Gastrointestin Liver Dis. 2022 Dec 17;31(4):437-443. doi: 10.15403/jgld-4472. PMID: 36535062. 18: Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol. 2022 Dec 7;28(45):6380-6396. doi: 10.3748/wjg.v28.i45.6380. PMID: 36533109; PMCID: PMC9753050. 19: Zha J, Jiang Q, Yao BB, Cohen DE, Carter DC, Menon RM. Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects. Pharmacol Res Perspect. 2022 Dec;10(6):e01024. doi: 10.1002/prp2.1024. PMID: 36416673; PMCID: PMC9683076. 20: Alarfaj SJ, Alzahrani A, Alotaibi A, Almutairi M, Hakami M, Alhomaid N, Alharthi N, Korayem GB, Alghamdi A. The effectiveness and safety of direct- acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharm J. 2022 Oct;30(10):1448-1453. doi: 10.1016/j.jsps.2022.07.005. Epub 2022 Jul 25. PMID: 36387341; PMCID: PMC9649346.